EMA Releases Report on Parallel Scientific Advice with HTA Bodies
The European Medicines Agency report provides an analysis of the health-technology assessment pilot program, which began in 2010 and completed in March 2016.
The European Medicines Agency (EMA) released a report on March 31, 2016 detailing results from the pilot on parallel scientific advice with health-technology assessment (HTA) bodies that began in 2010 and completed at the end of March 2016. According to EMA, the initiative allows developers of new medicines to receive simultaneous feedback on their development plans from both regulators and HTA bodies.
In the report, EMA writes that the initiative has demonstrated positive outcomes and will be continued on an operational basis. EMA says this kind of parallel advice between regulators, HTA bodies, and others offer a key platform to discuss the development of new medicines, and facilitates access to these medications.
EMA notes parallel scientific advice during a drug’s early development process is “necessary to learn about data requirements at an early stage in the medicine’s development process, and to learn about divergent data requirements between regulators and [Health Technology Assessment Bodies] HTABs, and between participating HTA bodies.” The agency says the focus of the initiative was a project reviewing information on benefits and risks of a medicine how a medicine in the European Public Assessment reports could address the needs of HTABs.
In an analysis of the pilot program, EMA says that by the end of December 2015, the overall number of completed procedures for all regulatory-HTA scientific advances is 63, an increase since the start of the program in 2010. The agency conduced a comparative analysis of 31 procedures between 2010 and May 2015. According to EMA, this analysis indicates there was a “high level of full or partial alignment between regulators and HTAB across all domains at the culmination of the procedure.” For this reason, the agency says parallel scientific advice with HTA bodies and other relevant stakeholders will now be routinely offered.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
